NEW YORK, Dec. 4, 2014 /PRNewswire/ -- Wolf Popper LLP is
investigating claims on behalf of investors in Avanir
Pharmaceuticals, Inc. (NASDAQ: AVNR), concerning the proposed
acquisition of Avanir by Otsuka Pharmaceutical Co., Ltd.
Avanir shareholders seeking more information about this
acquisition are advised to contact Carl
Stine at (212) 759-4600 or cstine@wolfpopper.com.
The investigation concerns whether the Avanir directors are
breaching their fiduciary duties by failing to adequately maximize
shareholder value. Under the terms of the merger agreement,
Avanir shareholders will receive $17.00 in cash for each share of Avanir they
own. The proposed transaction has an equity value of
$2.9 billion. However, the
offer price is below the median Street price target of $17.71 per share.
Wolf Popper LLP has extensive experience representing investors
in mergers and acquisition lawsuits and has successfully ensured
that investors receive the maximum compensation. Twelve Wolf
Popper attorneys were named Rising Stars or Super Lawyers in the
2014 Super Lawyers New York City Metro Edition, including
Wolf Popper partner Carl Stine, who was included in the Super
Lawyers Top 100 List for the New York
City Metro area. View Wolf Popper attorney biographies
at www.wolfpopper.com.
Attorney Advertising: Prior Results Do Not Guarantee A Similar
Outcome.
Wolf Popper LLP
845 Third Avenue
New York, New York 10022
Telephone: 212-759-4600
Toll Free Tel: 877-370-7703
Toll Free Fax: 877-370-7704
Email: cstine@wolfpopper.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wolf-popper-llp-investigates-claims-that-the-proposed-acquisition-of-avanir-pharmaceuticals-inc-may-not-be-in-the-best-interests-of-its-investors-300005006.html
SOURCE Wolf Popper LLP